

EMERGING COMPANY PROFILE | REPRINT FROM OCT. 15, 2021

Origami: Correcting or eliminating misfolded proteins

BY DANIELLE GOLOVIN, STAFF WRITER



BIOCENTURY & GETTY IMAGES

As pharma were exiting neuroscience in droves around 2015, Origami President and CEO Beth Hoffman decided to take the opposite tack: leveraging her background in neuroscience and protein folding correctors to bring a fresh MOA to the space.

Origami Therapeutics Inc. is gearing up to raise a seed round to fund the start-up, which is initially focusing on Huntington disease, said Hoffman, who was VP, discovery biology at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in 2007-14. During that time, one of her scientists showed her data that a small molecule could turn a misfolded, non-functional protein into a properly folded, functional protein.

The small molecule was VX-809, now lumacaftor, the CFTR-targeting conformation corrector portion of cystic fibrosis drug Orkambi lumacaftor/ivacaftor. “It not only helps people get better, but over time the lungs can actually heal,” Hoffman told BioCentury. “It’s amazing what a small molecule can do to leverage a cell’s own biology.”

She said she could imagine a way to leverage the concept of conformation correctors to treat neurodegenerative diseases, as many are caused by protein misfolding.

Vyndamax tafamidis from Pfizer Inc. (NYSE:PFE) and Oxbryta voxelotor from Global Blood Therapeutics Inc. are marketed conformation correctors to treat transthyretin amyloid cardiomyopathy and sickle cell disease, respectively.

“I would say that the concept of a small molecule modulating protein folding has been demonstrated as a clearly viable approach,” said Hoffman.

Origami’s drug discovery platform, ORICISION, enables discovery of small molecule protein degraders and conformation correctors and then uses patient-derived disease models to match the best therapy type to treat each neurodegenerative disease.

The company chose Huntington disease as its first focus because the well understood disease biology and clinical development feasibility. “We know who to treat, roughly when to treat and what to measure,” said Hoffman.

Huntington disease patients have an increased number of CAG repeats in their HTT gene, leading to a mutated protein (mHTT) that can misfold and form toxic aggregates, often

called inclusion bodies. A conformation corrector could stabilize mHTT in a wild-type-like conformation and prevent aggregation. The company is selecting brain penetrant molecules to treat all organs and cells in the body, most of which have demonstrated pathology in the indication.

Origami identifies conformation correctors using a combination of cell-based and biochemical assays, such as limited proteolysis. “If a protein unfolds, then it’s more susceptible to being cleaved by proteases in the cell,” said Hoffman. Cell fractionation and various imaging techniques can reveal if a protein is in the proper place in the cell.

And most important is to look for restoration of protein function. “In the case of a receptor, you might look for a second messenger. In the case of CFTR, we looked for a restoration of the flux of chloride ions,” said Hoffman.

HTT is a scaffolding protein that doesn’t have a simple functional readout like flux of an ion. Instead, the company screened for compounds that reduced aggregation. ORI-503 prevented the accumulation of mHTT aggregates without altering overall mHTT levels.

“Mutant huntingtin itself is functional, and so you don’t want to get rid of all of it, you want to get rid of the misfolded portion,” said Hoffman.

Origami’s lead program, ORI-113, is an HTT degrader that selectively reduces mHTT protein, which in turn reduces aggregation. ORI-113 also restores more normal morphology of human neurons, as seen in a cell culture system of HD patient-derived neurons.

Proteins can be degraded by several cellular waste systems including the proteasome, autophagosome or lysosome. Hoffman said they don’t know yet which cellular system is in play for HTT degradation by their molecules. “By structure, these don’t look like they are binding to an E3 ligase like a

molecular glue or PROTAC might be. Now, part of what we’re doing is trying to understand the exact mechanism.”

Hoffman, who has self-funded the company so far, hopes to start a clinical trial in about three years, before which the company would seek series A funding.

The company is also interested in developing compounds for other neurodegenerative diseases with genetically identified targets that tend to misfold, such as APOE4 in Alzheimer’s disease, SNCA in Parkinson’s, various ataxins in spinocerebellar ataxias, and C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia.

Hoffman said Origami will stick to neurology indications, but the platform is applicable to any protein misfolding disease, and the company is open to partnerships.

COMPANY PROFILE ORIGAMI THERAPEUTICS INC.

San Diego, Calif.

Technology: Protein degrader and corrector platform

Origin of technology: In-house

Disease focus: Neurology

Clinical status: Preclinical

Founded: 2015 by Beth Hoffman

Academic collaborators: None

Corporate partners: N/A

Number of employees: 3

Funds raised: \$2 million

Investors: Self-funded

CEO: Beth Hoffman

Patents: None

BIOCENTURY

BIOCENTURY INC.

BioCentury's mission is to provide value-added business intelligence & analysis for life science companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.

NEWSROOM

news@biocentury.com

SAN CARLOS, CA

+1 650-595-5333; Fax: +1 650-595-5589

CHICAGO

+1 312-755-0798; Fax: +1 650-595-5589

WASHINGTON, DC

+1 202-462-9582; Fax: +1 202-667-2922

UNITED KINGDOM

+44 (0)1865-512184; Fax: +1 650-595-5589

BioCentury®; Because Real Intelligence is Hard to Find™; BCIQ™; The BioCentury 100™; and The Clear Route to ROI™ are trademarks of BIOCENTURY INC. All contents Copyright © 2021, BIOCENTURY INC. ALL RIGHTS RESERVED. No part of BioCentury's Publications or Website may be copied, reproduced, retransmitted, disseminated, sold, distributed, published, broadcast, circulated, commercially exploited in any form or used to create derivative works without the written consent of BioCentury. Information provided by BioCentury's Publications and Website is gathered from sources that BioCentury believes are reliable; however, BioCentury does not guarantee the accuracy, completeness, or timeliness of the information, nor does BioCentury make any warranties of any kind regarding the information. The contents of BioCentury's Publications and Website are not intended as investment, business, tax or legal advice, and BioCentury is not responsible for any investment, business, tax or legal opinions cited therein or for any decision made or action taken in reliance upon such information.

All use of BioCentury and its contents by current subscribers is governed by the BioCentury User Agreement and by all

others is governed by the BioCentury Terms of Use, unless a written agreement to the contrary has been executed by BioCentury Inc.

USE OF IMAGES: Certain Images used in BioCentury Inc.'s Publications, Video Content, Websites, Services, Notices and/or Marketing Materials are licensed from Getty Images (US), Inc. Any such image of a person or object so displayed is being used for illustrative purposes only and any such person or object depicted, if any, is merely a model. For more information see "Use of Images" found under the "Legal" section on the footer of the homepage at www.biocentury.com.

PRIVACY & ADVERTISING: In accordance with its Privacy Policy, BioCentury does NOT sell its customer information or usage data to third parties. BioCentury sells advertising in its BioCentury product emails and on its website. BioCentury is pleased to acknowledge its conference and events partners and sponsors through promotional announcements, on our web site, at our events and in our product emails. BioCentury also provides advertising opportunities to partners, sponsors, and advertisers through stand-alone emails to our community.